董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Isaac Israel | 男 | Director | 47 | 0.02万美元 | 49.55 | 2026-03-19 |
| Simcha Rock | 男 | Independent Director | 76 | 40.10万美元 | 未持股 | 2026-03-19 |
| Suzana Nahum Zilberberg | 女 | Independent Director | 54 | 未披露 | 未持股 | 2026-03-19 |
| Ido Agmon | 男 | Independent Director | 48 | 11.63万美元 | 未持股 | 2026-03-19 |
| Robert Gagnon | 男 | Independent Director | 52 | 未披露 | 未持股 | 2026-03-19 |
| Eric Rowinsky | 男 | Chairman of the Board and Independent Director | 69 | 未披露 | 未持股 | 2026-03-19 |
| Yael Margolin | 女 | Independent Director | 71 | 未披露 | 未持股 | 2026-03-19 |
| Gil Efron | 男 | Chief Executive Officer and Director | 60 | 0.06万美元 | 未持股 | 2026-03-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hadas Reuveni | 女 | Vice President of Research and Development | 58 | 0.03万美元 | 未持股 | 2026-03-19 |
| Michael Schickler | 男 | Head of Clinical and Regulatory Affairs | 67 | 0.03万美元 | 未持股 | 2026-03-19 |
| Shai Lankry | 男 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2026-03-19 |
| Gil Efron | 男 | Chief Executive Officer and Director | 60 | 0.06万美元 | 未持股 | 2026-03-19 |
| Shai Lankry | 男 | Chief Financial Officer | 50 | 0.01万美元 | 未持股 | 2026-03-19 |
董事简历
中英对照 | 中文 | 英文- Isaac Israel
-
Isaac Israel，他曾一直担任首席执行官兼董事会成员（2013年7月以来），以及首席执行官兼董事会成员（2012年10月以来）。他曾担任BeeContact公司（原为TASE：BCNT）的创始首席执行官（从2001年到2007年）。2008年以来，他曾一直担任Uneri Capital公司（他所有的资本市场领域的咨询公司，专门从事医疗保健行业）的创始首席执行官。提供上述咨询服务时，他也担任各种私人和上市医疗保健公司的董事会成员，包括担任NextGen Biomed公司（特拉维夫证券交易所上市公司）的董事会主席。2011年以来，他也为Capital Point公司（TASE：CPTP）提供商业开发服务。
Isaac Israel is a director and serves on compensation committee and on audit and financial statement examination committee. Mr. Israel served as a member of the board of directors since October 2012, and as chief executive officer of Purple Biotech (NASDAQ: PPBT) from 2012 until 2022 and served as Acting Chief Executive Officer from March 2023 to Augt 2023. Since 2008, Mr. Israel has served as founding chief executive officer of Uneri Capital Ltd., a consulting firm, owned by Mr. Israel, which specializes in the healthcare sector. Mr. Israel was the founding chief executive officer of BeeContact Ltd. (formerly TASE: BCNT), from 2001 until 2007. Mr. Israel served as a member of the board of directors of vario private and public healthcare corporations, including as chairman of the board of a public healthcare corporation, NextGen Biomed Ltd. (TASE: NXGN). - Isaac Israel，他曾一直担任首席执行官兼董事会成员（2013年7月以来），以及首席执行官兼董事会成员（2012年10月以来）。他曾担任BeeContact公司（原为TASE：BCNT）的创始首席执行官（从2001年到2007年）。2008年以来，他曾一直担任Uneri Capital公司（他所有的资本市场领域的咨询公司，专门从事医疗保健行业）的创始首席执行官。提供上述咨询服务时，他也担任各种私人和上市医疗保健公司的董事会成员，包括担任NextGen Biomed公司（特拉维夫证券交易所上市公司）的董事会主席。2011年以来，他也为Capital Point公司（TASE：CPTP）提供商业开发服务。
- Isaac Israel is a director and serves on compensation committee and on audit and financial statement examination committee. Mr. Israel served as a member of the board of directors since October 2012, and as chief executive officer of Purple Biotech (NASDAQ: PPBT) from 2012 until 2022 and served as Acting Chief Executive Officer from March 2023 to Augt 2023. Since 2008, Mr. Israel has served as founding chief executive officer of Uneri Capital Ltd., a consulting firm, owned by Mr. Israel, which specializes in the healthcare sector. Mr. Israel was the founding chief executive officer of BeeContact Ltd. (formerly TASE: BCNT), from 2001 until 2007. Mr. Israel served as a member of the board of directors of vario private and public healthcare corporations, including as chairman of the board of a public healthcare corporation, NextGen Biomed Ltd. (TASE: NXGN).
- Simcha Rock
-
Simcha Rock，他曾一直担任我们的首席财务官和董事会成员（2013年7月以来）。他曾担任Edmond de Rothschild Private Equity Management公司（公司专门从事风险投资的管理，以及其它私人股权投资基金）的私人股本经理（从2000年2月到2011年1月），负责多个投资基金的所有财务、法律和行政事务。2000年之前，他曾担任Intel Electronics公司、The Jerusalem College of Technology、JC Technologies公司的财务管理职务。他持有Yeshiva University的学士学位，以及Cleveland State University的工商管理硕士学位。
Simcha Rock has served as a member of Purple Biotech's Board since July 2013. Mr. Rock served as Chief Financial Officer from July 2013 until he retired from such position as of December 31, 2018, and subsequently served as a strategic consultant to until December 31, 2019. Prior to joining , Mr. Rock was a private equity manager at Edmond de Rothschild Private Equity Management, a firm specializing in the management of venture capital and other private equity investments funds, from February 2000 until January 2011, with responsibility for all financial, legal and administrative matters for several investment funds. Prior to 2000, Mr. Rock held financial management positions at Intel Electronics Ltd., The Jeralem College of Technology, and JC Technologies Ltd. Mr. Rock holds a B.A. degree from Yeshiva University and an MBA degree from Cleveland State University. - Simcha Rock，他曾一直担任我们的首席财务官和董事会成员（2013年7月以来）。他曾担任Edmond de Rothschild Private Equity Management公司（公司专门从事风险投资的管理，以及其它私人股权投资基金）的私人股本经理（从2000年2月到2011年1月），负责多个投资基金的所有财务、法律和行政事务。2000年之前，他曾担任Intel Electronics公司、The Jerusalem College of Technology、JC Technologies公司的财务管理职务。他持有Yeshiva University的学士学位，以及Cleveland State University的工商管理硕士学位。
- Simcha Rock has served as a member of Purple Biotech's Board since July 2013. Mr. Rock served as Chief Financial Officer from July 2013 until he retired from such position as of December 31, 2018, and subsequently served as a strategic consultant to until December 31, 2019. Prior to joining , Mr. Rock was a private equity manager at Edmond de Rothschild Private Equity Management, a firm specializing in the management of venture capital and other private equity investments funds, from February 2000 until January 2011, with responsibility for all financial, legal and administrative matters for several investment funds. Prior to 2000, Mr. Rock held financial management positions at Intel Electronics Ltd., The Jeralem College of Technology, and JC Technologies Ltd. Mr. Rock holds a B.A. degree from Yeshiva University and an MBA degree from Cleveland State University.
- Suzana Nahum Zilberberg
-
Suzana Nahum Zilberberg，2011年5月以来，她一直担任首席执行官。她也是Micromedic公司的副主席。加入公司之前，她曾任职Teva公司12年，担任多种职务，最后担任亚洲及太平洋地区的副总裁，领导Teva公司渗透到日本和中国。她也曾于2008年领导完成公司与Kowa Pharmaceuticals公司的合资公司协议，并于2009年公司收购Taisho Pharmaceutical Co.（推动Teva公司成为日本第五大通用制药公司）。她持有Tel Aviv University的会计和经济学学士学位、Tel Aviv University的财务和营销方向的工商管理硕士学位，也是注册会计师。
Suzana Nahum Zilberberg has served as chief executive officer since May 2011. Ms. Nahum Zilberberg is also the vice chairman of Micromedic. Prior to joining company, Ms. Nahum Zilberberg worked at Teva for 12 years in several positions, her last role being Vice President Asia and Pacific, leading the penetration of Teva into Japan and China. In her position, Ms. Nahum Zilberberg led the team that finalized the joint venture agreement with Kowa Pharmaceuticals, Inc. in 2008 and the acquisition of Taisho Pharmaceutical Co., Ltd., in 2009 which resulted in Teva becoming the fifth largest generic pharmaceutical company in Japan. Ms. Nahum Zilberberg holds a BA in Accounting and Economics from Tel Aviv University, an MBA in Finance and Marketing from Tel Aviv University and is a Certified Public Accountant. - Suzana Nahum Zilberberg，2011年5月以来，她一直担任首席执行官。她也是Micromedic公司的副主席。加入公司之前，她曾任职Teva公司12年，担任多种职务，最后担任亚洲及太平洋地区的副总裁，领导Teva公司渗透到日本和中国。她也曾于2008年领导完成公司与Kowa Pharmaceuticals公司的合资公司协议，并于2009年公司收购Taisho Pharmaceutical Co.（推动Teva公司成为日本第五大通用制药公司）。她持有Tel Aviv University的会计和经济学学士学位、Tel Aviv University的财务和营销方向的工商管理硕士学位，也是注册会计师。
- Suzana Nahum Zilberberg has served as chief executive officer since May 2011. Ms. Nahum Zilberberg is also the vice chairman of Micromedic. Prior to joining company, Ms. Nahum Zilberberg worked at Teva for 12 years in several positions, her last role being Vice President Asia and Pacific, leading the penetration of Teva into Japan and China. In her position, Ms. Nahum Zilberberg led the team that finalized the joint venture agreement with Kowa Pharmaceuticals, Inc. in 2008 and the acquisition of Taisho Pharmaceutical Co., Ltd., in 2009 which resulted in Teva becoming the fifth largest generic pharmaceutical company in Japan. Ms. Nahum Zilberberg holds a BA in Accounting and Economics from Tel Aviv University, an MBA in Finance and Marketing from Tel Aviv University and is a Certified Public Accountant.
- Ido Agmon
-
Ido Agmon，拥有工商管理硕士学位，并担任我们的董事会成员（2016年6月26日以来）。2014年以来，他一直担任Aviv New-Tech（原为Aviv Bio-Invest，私人投资基金，管理公共以色列与全球生物医学和技术公司的投资组合）的经理，也担任其联席创始人，在那里他曾负责以色列和全球生物医学公司的投资分析和评估。2012年以来，他也一直担任独立顾问，提供初创和技术风险的筹资战略规划和建议。2009年至2011年，他曾担任Meytav Technology Incubator（生物技术、制药和医学技术的以色列加速器，涉及20多个投资组合公司企业）的首席执行官。他曾担任许多生物医学企业的董事会成员。2007年至2009年，他曾担任ATI incubator（技术孵化器，专门从事生物医学和清洁技术项目）的商业开发主管，负责交易流和项目评估。他持有Tel Aviv University（位于以色列特拉维夫）的工商管理和生命科学学士学位，以及The Hebrew University（以色列耶路撒冷）的工商管理硕士学位。
Ido Agmon has served as a member of Purple Biotech's Board since June 2016. Since 2012, Mr. Agmon has been acting as an independent consultant and investment manager, providing start ups, investment funds and technology based ventures with advice in strategic and financial planning, fund raising and related biness development activities. From 2014 until the end of 2016, Mr. Agmon was a manager of Aviv New Tech (formerly Aviv Bio Invest), a private investment fund which manages a portfolio of public Israeli and global biomed and technology companies, of which he was a co founder, and where he was responsible for analysis and evaluation of investments in Israeli and global biomed companies. From 2009 until 2011, Mr. Agmon served as the chief executive officer of Meytav Technology Incubator, an Israeli based accelerator for biotech, pharma & medtech ventures with over 20 portfolio companies. Mr. Agmon has served as a board member at several biomed ventures. From 2007 until 2009, Mr. Agmon served as the Director of Biness Development at ATI incubator, a technology incubator specializing in biomed and cleantech projects, responsible for deal flow and project evaluation. Mr. Agmon holds a B.A. degree in Biness Administration and Life Sciences from Tel Aviv University, Tel Aviv, Israel, and an MBA degree from the Hebrew University of Jeralem, Israel. - Ido Agmon，拥有工商管理硕士学位，并担任我们的董事会成员（2016年6月26日以来）。2014年以来，他一直担任Aviv New-Tech（原为Aviv Bio-Invest，私人投资基金，管理公共以色列与全球生物医学和技术公司的投资组合）的经理，也担任其联席创始人，在那里他曾负责以色列和全球生物医学公司的投资分析和评估。2012年以来，他也一直担任独立顾问，提供初创和技术风险的筹资战略规划和建议。2009年至2011年，他曾担任Meytav Technology Incubator（生物技术、制药和医学技术的以色列加速器，涉及20多个投资组合公司企业）的首席执行官。他曾担任许多生物医学企业的董事会成员。2007年至2009年，他曾担任ATI incubator（技术孵化器，专门从事生物医学和清洁技术项目）的商业开发主管，负责交易流和项目评估。他持有Tel Aviv University（位于以色列特拉维夫）的工商管理和生命科学学士学位，以及The Hebrew University（以色列耶路撒冷）的工商管理硕士学位。
- Ido Agmon has served as a member of Purple Biotech's Board since June 2016. Since 2012, Mr. Agmon has been acting as an independent consultant and investment manager, providing start ups, investment funds and technology based ventures with advice in strategic and financial planning, fund raising and related biness development activities. From 2014 until the end of 2016, Mr. Agmon was a manager of Aviv New Tech (formerly Aviv Bio Invest), a private investment fund which manages a portfolio of public Israeli and global biomed and technology companies, of which he was a co founder, and where he was responsible for analysis and evaluation of investments in Israeli and global biomed companies. From 2009 until 2011, Mr. Agmon served as the chief executive officer of Meytav Technology Incubator, an Israeli based accelerator for biotech, pharma & medtech ventures with over 20 portfolio companies. Mr. Agmon has served as a board member at several biomed ventures. From 2007 until 2009, Mr. Agmon served as the Director of Biness Development at ATI incubator, a technology incubator specializing in biomed and cleantech projects, responsible for deal flow and project evaluation. Mr. Agmon holds a B.A. degree in Biness Administration and Life Sciences from Tel Aviv University, Tel Aviv, Israel, and an MBA degree from the Hebrew University of Jeralem, Israel.
- Robert Gagnon
-
Robert Gagnon目前在Opus Genetics担任首席财务官，他于2025年8月开始担任这一职务。在此之前，他于2023年3月至2025年8月担任Remix Therapeutics的首席财务官，于2022年10月至2023年6月担任医疗健康风险投资和私募股权基金Gurnet Point Capital的运营合伙人，于2018年8月至2022年10月担任Verastem，于2013年11月至2018年8月担任哈佛生物科学，于2012年至2013年担任清洁海港，Inc.的运营合伙人。他的职业经历还包括在渤健 Idec、德勤会计师事务所和普华永道担任高级职务。加格农先生在麻省理工学院斯隆获得工商管理硕士学位，在本特利学院获得会计学士学位。
Robert Gagnon is currently the Chief Financial Officer at Opus Genetics, a role he started in August 2025. Prior to that, he served as CFO for Remix Therapeutics from March 2023 to August 2025, as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund, from October 2022 to June 2023, Verastem, Inc. from August 2018 to October 2022, Harvard Bioscience, Inc. from November 2013 to August 2018, and Clean Harbors, Inc. between 2012 and 2013. His professional experience also includes senior roles at Biogen Idec, Deloitte & Touche, and PricewaterhouseCoopers. Mr. Gagnon earned his M.B.A. from MIT Sloan and a B.A. in accounting from Bentley College. - Robert Gagnon目前在Opus Genetics担任首席财务官，他于2025年8月开始担任这一职务。在此之前，他于2023年3月至2025年8月担任Remix Therapeutics的首席财务官，于2022年10月至2023年6月担任医疗健康风险投资和私募股权基金Gurnet Point Capital的运营合伙人，于2018年8月至2022年10月担任Verastem，于2013年11月至2018年8月担任哈佛生物科学，于2012年至2013年担任清洁海港，Inc.的运营合伙人。他的职业经历还包括在渤健 Idec、德勤会计师事务所和普华永道担任高级职务。加格农先生在麻省理工学院斯隆获得工商管理硕士学位，在本特利学院获得会计学士学位。
- Robert Gagnon is currently the Chief Financial Officer at Opus Genetics, a role he started in August 2025. Prior to that, he served as CFO for Remix Therapeutics from March 2023 to August 2025, as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund, from October 2022 to June 2023, Verastem, Inc. from August 2018 to October 2022, Harvard Bioscience, Inc. from November 2013 to August 2018, and Clean Harbors, Inc. between 2012 and 2013. His professional experience also includes senior roles at Biogen Idec, Deloitte & Touche, and PricewaterhouseCoopers. Mr. Gagnon earned his M.B.A. from MIT Sloan and a B.A. in accounting from Bentley College.
- Eric Rowinsky
-
Eric Rowinsky是一级董事，自2017年5月以来一直担任我们的董事会成员。Rowinsky博士自2016年6月起担任Rgenix，Inc.的执行董事兼总裁。他还自2016年6月起担任ClearPath Development Co.的首席科学官。在此之前，罗温斯基博士于2011年2月至2016年1月担任StemlineTherapeutics，Inc.研究与开发主管，首席医疗官兼执行Vice President。2010年，Rowinsky博士共同创立Primrose Therapeutics，并成为其首席执行官，直到2011年被收购。从2005年到2010年，他曾担任Imclone Systems Incorporated公司（生命科学公司，专注于单克隆抗体，被礼来公司公司收购）的首席医疗官兼负责临床开发和监管事务的执行Vice President。在此之前，Rowinsky博士在癌症治疗和研究中心的药物开发研究所担任几个职位，包括研究所主任和SBC Endowed Chair for Early Drug Development。此前，他曾担任the University of Texas Health Science Center at San Antonio的医学肿瘤学部门的医学临床教授，以及Johns Hopkins University School of Medicine的肿瘤学副教授。自2011年以来，Rowinsky博士一直担任Biogen Idec，Inc.、Kitov Pharmaceuticals，Inc.和Fortress Biosciences，Inc.的董事会成员，并曾在BIND Therapeutics被辉瑞和NavideaBiopharmaceuticals，Inc.收购之前担任其董事会成员。Rowinsky博士在纽约大学（New York University）获得文科学士学位，并在范德堡大学（Vanderbilt University）获得医学博士学位。
Eric Rowinsky has served as the Chairman of Purple Biotech's Board since October 2019. Dr. Eric Rowinsky's principal expertise is in the development and registration of novel therapeutics to treat cancer and related disorders.From 1996 to 2006, Dr. Rowinsky was a Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at The Johns Hopkins University School of Medicine. Dr. Rowinsky was a longstanding National Cancer Institute principal and co principal investigator from 1990 to 2004, and was integrally involved in pivotal clinical and preclinical investigations that led to the development of numero cancer therapeutics, including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib, ramucirumab, tagraxofp and temsirolim among others. Dr. Rowinsky was also an Adjunct Professor of Medicine at New York University School of Medicine (2008 2018). Dr. Rowinsky presently serves on the boards of directors of the public companies Biogen Idec, Inc., Biosciences, Inc. and Verastem Inc. Dr. Rowinsky formerly served on the boards of directors of the public companies Fortress Biosciences, Inc. (2010 2025), Navidea Biopharmaceuticals Inc. (2010 2018), BIND Therapeutics (2014 2016), and Biophytis S.A. (2018 2019), as ll as at a number of privately held companies. Dr. Rowinsky received a B.A. degree from New York University (1977) and an M.D. degree from Vanderbilt University School of Medicine (1981). Dr. Rowinsky completed his residency in internal medicine at the University of California, San Diego (1984) and completed his fellowship in medical oncology at The Johns Hopkins Oncology Center (1987). - Eric Rowinsky是一级董事，自2017年5月以来一直担任我们的董事会成员。Rowinsky博士自2016年6月起担任Rgenix，Inc.的执行董事兼总裁。他还自2016年6月起担任ClearPath Development Co.的首席科学官。在此之前，罗温斯基博士于2011年2月至2016年1月担任StemlineTherapeutics，Inc.研究与开发主管，首席医疗官兼执行Vice President。2010年，Rowinsky博士共同创立Primrose Therapeutics，并成为其首席执行官，直到2011年被收购。从2005年到2010年，他曾担任Imclone Systems Incorporated公司（生命科学公司，专注于单克隆抗体，被礼来公司公司收购）的首席医疗官兼负责临床开发和监管事务的执行Vice President。在此之前，Rowinsky博士在癌症治疗和研究中心的药物开发研究所担任几个职位，包括研究所主任和SBC Endowed Chair for Early Drug Development。此前，他曾担任the University of Texas Health Science Center at San Antonio的医学肿瘤学部门的医学临床教授，以及Johns Hopkins University School of Medicine的肿瘤学副教授。自2011年以来，Rowinsky博士一直担任Biogen Idec，Inc.、Kitov Pharmaceuticals，Inc.和Fortress Biosciences，Inc.的董事会成员，并曾在BIND Therapeutics被辉瑞和NavideaBiopharmaceuticals，Inc.收购之前担任其董事会成员。Rowinsky博士在纽约大学（New York University）获得文科学士学位，并在范德堡大学（Vanderbilt University）获得医学博士学位。
- Eric Rowinsky has served as the Chairman of Purple Biotech's Board since October 2019. Dr. Eric Rowinsky's principal expertise is in the development and registration of novel therapeutics to treat cancer and related disorders.From 1996 to 2006, Dr. Rowinsky was a Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at The Johns Hopkins University School of Medicine. Dr. Rowinsky was a longstanding National Cancer Institute principal and co principal investigator from 1990 to 2004, and was integrally involved in pivotal clinical and preclinical investigations that led to the development of numero cancer therapeutics, including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib, ramucirumab, tagraxofp and temsirolim among others. Dr. Rowinsky was also an Adjunct Professor of Medicine at New York University School of Medicine (2008 2018). Dr. Rowinsky presently serves on the boards of directors of the public companies Biogen Idec, Inc., Biosciences, Inc. and Verastem Inc. Dr. Rowinsky formerly served on the boards of directors of the public companies Fortress Biosciences, Inc. (2010 2025), Navidea Biopharmaceuticals Inc. (2010 2018), BIND Therapeutics (2014 2016), and Biophytis S.A. (2018 2019), as ll as at a number of privately held companies. Dr. Rowinsky received a B.A. degree from New York University (1977) and an M.D. degree from Vanderbilt University School of Medicine (1981). Dr. Rowinsky completed his residency in internal medicine at the University of California, San Diego (1984) and completed his fellowship in medical oncology at The Johns Hopkins Oncology Center (1987).
- Yael Margolin
-
Yael Margolin在风险投资、制药和生物技术行业拥有超过35年的担任高级经理、首席执行官和董事会成员的经验，领导战略和业务规划、融资、团队建设、产品开发和企业伙伴关系。从2005年到2019年，Margolin博士担任临床阶段生物制药公司Gamida CellLtd.的总裁，首席执行官兼董事，领导公司从临床前开发到3期国际注册研究。在此之前，Margolin博士是专注于梦百合的风险投资公司Denali Ventures LLC的Vice President，也是Teva Pharmaceuticals的项目经理。Margolin博士持有以色列特拉维夫大学（Tel Aviv University）微生物系的生物学理学学士学位和理学硕士学位，以及雷霍沃特魏茨曼科学研究所（Weitzman Institute of Science）膜研究系的博士学位，Yael University School of Medicine的博士后。
Yael Margolin joined the board of directors in 2020. Dr. Margolin has more than 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. From 2005 to 2019, Dr. Margolin served as President, Chief Executive Officer and director of Gamida Cell Ltd., a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, Dr. Margolin was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a bachelor of science in biology and a master of science Cum Laude from the department of microbiology, both from Tel Aviv University in Israel, a Ph.D. From the department of membrane research at the Weitzman Institute of Science in Rehovot, Israel and was a post doctoral associate at the Yale University School of Medicine. - Yael Margolin在风险投资、制药和生物技术行业拥有超过35年的担任高级经理、首席执行官和董事会成员的经验，领导战略和业务规划、融资、团队建设、产品开发和企业伙伴关系。从2005年到2019年，Margolin博士担任临床阶段生物制药公司Gamida CellLtd.的总裁，首席执行官兼董事，领导公司从临床前开发到3期国际注册研究。在此之前，Margolin博士是专注于梦百合的风险投资公司Denali Ventures LLC的Vice President，也是Teva Pharmaceuticals的项目经理。Margolin博士持有以色列特拉维夫大学（Tel Aviv University）微生物系的生物学理学学士学位和理学硕士学位，以及雷霍沃特魏茨曼科学研究所（Weitzman Institute of Science）膜研究系的博士学位，Yael University School of Medicine的博士后。
- Yael Margolin joined the board of directors in 2020. Dr. Margolin has more than 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. From 2005 to 2019, Dr. Margolin served as President, Chief Executive Officer and director of Gamida Cell Ltd., a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, Dr. Margolin was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a bachelor of science in biology and a master of science Cum Laude from the department of microbiology, both from Tel Aviv University in Israel, a Ph.D. From the department of membrane research at the Weitzman Institute of Science in Rehovot, Israel and was a post doctoral associate at the Yale University School of Medicine.
- Gil Efron
-
Gil Efron，2011年起担任本公司的首席财务官。他有着20多年的各种财务管理职位的任职经验。他还是GEO Consulting Ltd.的所有人、首席执行官，他在2011年2月创办该公司，主要提供财务管理服务。2006年2月至2011年，他担任RRsat Global Communications（纳斯达克代码：RRST）的首席财务官，该公司为电视和电台广播公司提供发行与内容管理的服务。此前，他曾在多个公司担任过多个财务职位，其中包括Proficiency Ltd.的首席财务官、IP Planet Network Ltd.的首席财务官、PricewaterhouseCoopers以色列成员公司的高级审计师。他也曾担任Poalim Ventures I Ltd.的董事。他是以色列的注册会计师，获得了Hebrew University of Jerusalem的经济与会计学士学位、工商管理硕士学位。
Gil Efron has served as Chief Executive Officer since July 2022 and has served as a member of Purple Biotech's Board since March 2026. Prior to that, Mr. Efron served as Acting Chief Financial Officer from November 2024 to May 2025. Prior to that, Mr. Efron served as President and Chief Financial Officer since June 2021. Prior to that, Mr. Efron served as Deputy Chief Executive Officer and Chief Financial Officer, from October 2018. Prior to joining , Mr. Efron served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual listed plasma derived protein therapeutics company, from September 2011 to November 2017. Prior to that, Mr. Efron served as the CFO of NASDAQ listed RRsat Global Communications Ltd. (Nasdaq: RRST), from September 2005 to March 2011. Prior to that, Mr. Efron served in vario finance executive positions. Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Biness Administration from the Hebrew University of Jeralem and was granted a certified public accountant's license (non active) in Israel. - Gil Efron，2011年起担任本公司的首席财务官。他有着20多年的各种财务管理职位的任职经验。他还是GEO Consulting Ltd.的所有人、首席执行官，他在2011年2月创办该公司，主要提供财务管理服务。2006年2月至2011年，他担任RRsat Global Communications（纳斯达克代码：RRST）的首席财务官，该公司为电视和电台广播公司提供发行与内容管理的服务。此前，他曾在多个公司担任过多个财务职位，其中包括Proficiency Ltd.的首席财务官、IP Planet Network Ltd.的首席财务官、PricewaterhouseCoopers以色列成员公司的高级审计师。他也曾担任Poalim Ventures I Ltd.的董事。他是以色列的注册会计师，获得了Hebrew University of Jerusalem的经济与会计学士学位、工商管理硕士学位。
- Gil Efron has served as Chief Executive Officer since July 2022 and has served as a member of Purple Biotech's Board since March 2026. Prior to that, Mr. Efron served as Acting Chief Financial Officer from November 2024 to May 2025. Prior to that, Mr. Efron served as President and Chief Financial Officer since June 2021. Prior to that, Mr. Efron served as Deputy Chief Executive Officer and Chief Financial Officer, from October 2018. Prior to joining , Mr. Efron served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual listed plasma derived protein therapeutics company, from September 2011 to November 2017. Prior to that, Mr. Efron served as the CFO of NASDAQ listed RRsat Global Communications Ltd. (Nasdaq: RRST), from September 2005 to March 2011. Prior to that, Mr. Efron served in vario finance executive positions. Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Biness Administration from the Hebrew University of Jeralem and was granted a certified public accountant's license (non active) in Israel.
高管简历
中英对照 | 中文 | 英文- Hadas Reuveni
Hadas Reuveni自2017年以来一直担任该公司的Vice President研究与开发。Reuveni博士是Tyrnovo技术的共同发明者，在耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得抗癌药物发现博士学位。她自2005年以来一直从事Tyrnovo&；8217；s投资组合中的科学项目，并在生物技术方面拥有近20年的研究与开发经验。Reuveni博士创立了Novotyr Ltd.，这是一家生物技术初创公司，是Tyrnovo的前身公司，开发用于治疗癌症和神经退行性疾病的小分子，在那里她从2005年到2012年担任首席执行官。她还创立并担任Angiob Ltd.的董事和首席科学官，这是一家初创公司，为2006-2010年的多个适应症开发基于GPCR的代理商。在担任这些职务之前，她于2001年至2004年担任Keryx Biopharmaceuticals NASDAQ:KRX的研发总监。Reuveni博士曾担任Integra Holdings Ltd.，Campus Bio Management Ltd.和BioLinerx NASDAQ/TASE BLRX的科学顾问。
Hadas Reuveni has served as the Company's Vice President of Research and Development since 2017. Dr. Reuveni, a co inventor of the TyrNovo technology, received her Ph.D., summa cum laude, for anti cancer drug discovery from the Hebrew University of Jeralem. Dr. Reuveni managed the discovery and the preclinical development of TyrNovo's portfolio since 2005 and has more than two decades of research and development experience in biotechnology. From 2005 to 2012, Dr. Reuveni served as the Chief Executive Officer of NovoTyr Ltd., a biotechnology start up company, a predecessor company to TyrNovo, developing small molecules for the treatment of cancer and neurodegenerative diseases, which was established by Dr. Reuveni and Prof. Levitzki in 2005. Dr. Reuveni also founded and served as a director and Chief Scientific Officer of AngioB Ltd., a start up company that developed GPCR based agents for multiple indications, beten 2006 2010. Prior to these roles, Dr. Reuveni was the Director of Research & Development at Keryx Biopharmaceuticals (NASDAQ:KRX) beten 2001 2004. Dr. Reuveni has served as a scientific consultant for Integra Holdings Ltd., Camp Bio Management Ltd. and BioLineRX (NASDAQ/TASE BLRX). Dr. Reuveni holds a B.Sc. degree in chemistry, an M.Sc. degree in biological chemistry and a Ph.D. in biological chemistry and drug discovery, all from the Hebrew University of Jeralem, Israel.- Hadas Reuveni自2017年以来一直担任该公司的Vice President研究与开发。Reuveni博士是Tyrnovo技术的共同发明者，在耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得抗癌药物发现博士学位。她自2005年以来一直从事Tyrnovo&；8217；s投资组合中的科学项目，并在生物技术方面拥有近20年的研究与开发经验。Reuveni博士创立了Novotyr Ltd.，这是一家生物技术初创公司，是Tyrnovo的前身公司，开发用于治疗癌症和神经退行性疾病的小分子，在那里她从2005年到2012年担任首席执行官。她还创立并担任Angiob Ltd.的董事和首席科学官，这是一家初创公司，为2006-2010年的多个适应症开发基于GPCR的代理商。在担任这些职务之前，她于2001年至2004年担任Keryx Biopharmaceuticals NASDAQ:KRX的研发总监。Reuveni博士曾担任Integra Holdings Ltd.，Campus Bio Management Ltd.和BioLinerx NASDAQ/TASE BLRX的科学顾问。
- Hadas Reuveni has served as the Company's Vice President of Research and Development since 2017. Dr. Reuveni, a co inventor of the TyrNovo technology, received her Ph.D., summa cum laude, for anti cancer drug discovery from the Hebrew University of Jeralem. Dr. Reuveni managed the discovery and the preclinical development of TyrNovo's portfolio since 2005 and has more than two decades of research and development experience in biotechnology. From 2005 to 2012, Dr. Reuveni served as the Chief Executive Officer of NovoTyr Ltd., a biotechnology start up company, a predecessor company to TyrNovo, developing small molecules for the treatment of cancer and neurodegenerative diseases, which was established by Dr. Reuveni and Prof. Levitzki in 2005. Dr. Reuveni also founded and served as a director and Chief Scientific Officer of AngioB Ltd., a start up company that developed GPCR based agents for multiple indications, beten 2006 2010. Prior to these roles, Dr. Reuveni was the Director of Research & Development at Keryx Biopharmaceuticals (NASDAQ:KRX) beten 2001 2004. Dr. Reuveni has served as a scientific consultant for Integra Holdings Ltd., Camp Bio Management Ltd. and BioLineRX (NASDAQ/TASE BLRX). Dr. Reuveni holds a B.Sc. degree in chemistry, an M.Sc. degree in biological chemistry and a Ph.D. in biological chemistry and drug discovery, all from the Hebrew University of Jeralem, Israel.
- Michael Schickler
Michael Schickler自2020年1月起担任该公司临床运营主管。在担任该职位之前，Schickler博士担任FameWave的首席执行官，直到FameWave收购案结束。Schickler博士自2018年7月起还为医疗器械和梦百合公司提供咨询服务，就与生物制药药物开发有关的各种事项提供建议，包括自2019年3月起担任公司顾问。从2001年5月至2018年7月，Schickler博士担任CureTech Ltd.（一家生物技术公司，开发用于治疗和控制癌症的新型免疫疗法）的首席执行官。在CureTech任职期间，Schickler博士领导公司从运营的建立到发展成为临床阶段的公司，其活动横跨GMP制造和全球临床运营的基础研究。Schickler博士自2018年10月起担任CureTech董事会成员，自2017年3月起担任Accellta Ltd.董事会成员。Schickler博士在英国林肯大学（University of Lincoln，Lincoln，United Kingdom）获得工商管理文凭，在以色列雷霍沃特魏茨曼科学研究所（Weizmann Institute of Science）获得生物学博士学位，并获得理学硕士学位。免疫学学士学位和理学学士学位。以色列特拉维夫大学生命科学学院生物学学士学位。
Michael Schickler has served as the Company's Head of Clinical and Regulatory Affairs since January 2020. Prior to assuming this role, Dr. Schickler served as the Chief Executive Officer of FameWave until the closing of the FameWave Acquisition. Dr. Schickler has also provided consulting services for medical device and healthcare companies since July 2018, advising on vario matters pertaining to biopharmaceutical drug development, including as a consultant to the Company since March 2019. From May 2001 to July 2018, Dr. Schickler served as Chief Executive Officer of CureTech Ltd. ("CureTech"), a biotechnology company developing novel immunotherapies for the treatment and control of cancer. During his time at CureTech, Dr. Schickler led the company from the establishment of its operations through its development into a clinical stage company with activities spanning basic research through GMP manufacturing and worldwide clinical operations. Dr. Schickler has served on the board of directors of CureTech since October 2018 and previoly served on the board of directors of Accellta Ltd. Dr. Schickler received his Diploma in Biness Administration from the University of Lincoln, Lincoln, United Kingdom, his Ph.D. in Biology from The izmann Institute of Science, Rehovot, Israel and his B.Sc. degree in Biology from The Faculty of Life Sciences, Tel Aviv University, Israel.- Michael Schickler自2020年1月起担任该公司临床运营主管。在担任该职位之前，Schickler博士担任FameWave的首席执行官，直到FameWave收购案结束。Schickler博士自2018年7月起还为医疗器械和梦百合公司提供咨询服务，就与生物制药药物开发有关的各种事项提供建议，包括自2019年3月起担任公司顾问。从2001年5月至2018年7月，Schickler博士担任CureTech Ltd.（一家生物技术公司，开发用于治疗和控制癌症的新型免疫疗法）的首席执行官。在CureTech任职期间，Schickler博士领导公司从运营的建立到发展成为临床阶段的公司，其活动横跨GMP制造和全球临床运营的基础研究。Schickler博士自2018年10月起担任CureTech董事会成员，自2017年3月起担任Accellta Ltd.董事会成员。Schickler博士在英国林肯大学（University of Lincoln，Lincoln，United Kingdom）获得工商管理文凭，在以色列雷霍沃特魏茨曼科学研究所（Weizmann Institute of Science）获得生物学博士学位，并获得理学硕士学位。免疫学学士学位和理学学士学位。以色列特拉维夫大学生命科学学院生物学学士学位。
- Michael Schickler has served as the Company's Head of Clinical and Regulatory Affairs since January 2020. Prior to assuming this role, Dr. Schickler served as the Chief Executive Officer of FameWave until the closing of the FameWave Acquisition. Dr. Schickler has also provided consulting services for medical device and healthcare companies since July 2018, advising on vario matters pertaining to biopharmaceutical drug development, including as a consultant to the Company since March 2019. From May 2001 to July 2018, Dr. Schickler served as Chief Executive Officer of CureTech Ltd. ("CureTech"), a biotechnology company developing novel immunotherapies for the treatment and control of cancer. During his time at CureTech, Dr. Schickler led the company from the establishment of its operations through its development into a clinical stage company with activities spanning basic research through GMP manufacturing and worldwide clinical operations. Dr. Schickler has served on the board of directors of CureTech since October 2018 and previoly served on the board of directors of Accellta Ltd. Dr. Schickler received his Diploma in Biness Administration from the University of Lincoln, Lincoln, United Kingdom, his Ph.D. in Biology from The izmann Institute of Science, Rehovot, Israel and his B.Sc. degree in Biology from The Faculty of Life Sciences, Tel Aviv University, Israel.
- Shai Lankry
Shai Lankry自2025年5月起担任首席财务官职务。兰克里先生通过他的公司LS Consulting Services作为战略性零碎的首席财务官支持几家公司。2018年至2023年，兰克里先生担任Gamida Cell Ltd.（前身为GMDA）的首席财务官。在此之前，2016年至2018年，兰克里先生在ST Pharmaceutical Services，Inc.（NYSE：WST）担任财务总监，领导其以色列子公司的研发和运营的财务方面。2013年至2017年，Lankry先生担任MacroCure Ltd.（前身为纳斯达克：MCUR）的首席财务官和以色列站点经理，在该公司2014年在美国首次公开发行股票以及2017年被Leap Therapeutics Inc.（纳斯达克：LPTX）收购时发挥了不可或缺的作用。Lankry先生是一名持牌以色列注册会计师，拥有特拉维夫大学金融学工商管理硕士学位。
Shai Lankry has served as Chief Financial Officer since May 2025. Mr. Lankry supports several companies as a strategic fractional Chief Financial Officer through his firm, LS Consulting Services. From 2018 to 2023, Mr. Lankry served as the Chief Financial Officer of Gamida Cell Ltd. (formerly, Nasdaq: GMDA). Prior to that, from 2016 to 2018, Mr. Lankry served as Finance Director at st Pharmaceutical Services, Inc. (NYSE: WST), leading the financial aspects of research and development and operations for its Israeli subsidiary. From 2013 to 2017, Mr. Lankry served as the Chief Financial Officer and Israeli site manager of MacroCure Ltd. (formerly, Nasdaq: MCUR), where he played an integral role in its 2014 initial public offering in the United States and its 2017 acquisition by Leap Therapeutics Inc. (Nasdaq: LPTX). Mr. Lankry is a licensed Israeli certified public accountant and holds an M.B.A. degree in Finance from Tel Aviv University.- Shai Lankry自2025年5月起担任首席财务官职务。兰克里先生通过他的公司LS Consulting Services作为战略性零碎的首席财务官支持几家公司。2018年至2023年，兰克里先生担任Gamida Cell Ltd.（前身为GMDA）的首席财务官。在此之前，2016年至2018年，兰克里先生在ST Pharmaceutical Services，Inc.（NYSE：WST）担任财务总监，领导其以色列子公司的研发和运营的财务方面。2013年至2017年，Lankry先生担任MacroCure Ltd.（前身为纳斯达克：MCUR）的首席财务官和以色列站点经理，在该公司2014年在美国首次公开发行股票以及2017年被Leap Therapeutics Inc.（纳斯达克：LPTX）收购时发挥了不可或缺的作用。Lankry先生是一名持牌以色列注册会计师，拥有特拉维夫大学金融学工商管理硕士学位。
- Shai Lankry has served as Chief Financial Officer since May 2025. Mr. Lankry supports several companies as a strategic fractional Chief Financial Officer through his firm, LS Consulting Services. From 2018 to 2023, Mr. Lankry served as the Chief Financial Officer of Gamida Cell Ltd. (formerly, Nasdaq: GMDA). Prior to that, from 2016 to 2018, Mr. Lankry served as Finance Director at st Pharmaceutical Services, Inc. (NYSE: WST), leading the financial aspects of research and development and operations for its Israeli subsidiary. From 2013 to 2017, Mr. Lankry served as the Chief Financial Officer and Israeli site manager of MacroCure Ltd. (formerly, Nasdaq: MCUR), where he played an integral role in its 2014 initial public offering in the United States and its 2017 acquisition by Leap Therapeutics Inc. (Nasdaq: LPTX). Mr. Lankry is a licensed Israeli certified public accountant and holds an M.B.A. degree in Finance from Tel Aviv University.
- Gil Efron
Gil Efron，2011年起担任本公司的首席财务官。他有着20多年的各种财务管理职位的任职经验。他还是GEO Consulting Ltd.的所有人、首席执行官，他在2011年2月创办该公司，主要提供财务管理服务。2006年2月至2011年，他担任RRsat Global Communications（纳斯达克代码：RRST）的首席财务官，该公司为电视和电台广播公司提供发行与内容管理的服务。此前，他曾在多个公司担任过多个财务职位，其中包括Proficiency Ltd.的首席财务官、IP Planet Network Ltd.的首席财务官、PricewaterhouseCoopers以色列成员公司的高级审计师。他也曾担任Poalim Ventures I Ltd.的董事。他是以色列的注册会计师，获得了Hebrew University of Jerusalem的经济与会计学士学位、工商管理硕士学位。
Gil Efron has served as Chief Executive Officer since July 2022 and has served as a member of Purple Biotech's Board since March 2026. Prior to that, Mr. Efron served as Acting Chief Financial Officer from November 2024 to May 2025. Prior to that, Mr. Efron served as President and Chief Financial Officer since June 2021. Prior to that, Mr. Efron served as Deputy Chief Executive Officer and Chief Financial Officer, from October 2018. Prior to joining , Mr. Efron served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual listed plasma derived protein therapeutics company, from September 2011 to November 2017. Prior to that, Mr. Efron served as the CFO of NASDAQ listed RRsat Global Communications Ltd. (Nasdaq: RRST), from September 2005 to March 2011. Prior to that, Mr. Efron served in vario finance executive positions. Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Biness Administration from the Hebrew University of Jeralem and was granted a certified public accountant's license (non active) in Israel.- Gil Efron，2011年起担任本公司的首席财务官。他有着20多年的各种财务管理职位的任职经验。他还是GEO Consulting Ltd.的所有人、首席执行官，他在2011年2月创办该公司，主要提供财务管理服务。2006年2月至2011年，他担任RRsat Global Communications（纳斯达克代码：RRST）的首席财务官，该公司为电视和电台广播公司提供发行与内容管理的服务。此前，他曾在多个公司担任过多个财务职位，其中包括Proficiency Ltd.的首席财务官、IP Planet Network Ltd.的首席财务官、PricewaterhouseCoopers以色列成员公司的高级审计师。他也曾担任Poalim Ventures I Ltd.的董事。他是以色列的注册会计师，获得了Hebrew University of Jerusalem的经济与会计学士学位、工商管理硕士学位。
- Gil Efron has served as Chief Executive Officer since July 2022 and has served as a member of Purple Biotech's Board since March 2026. Prior to that, Mr. Efron served as Acting Chief Financial Officer from November 2024 to May 2025. Prior to that, Mr. Efron served as President and Chief Financial Officer since June 2021. Prior to that, Mr. Efron served as Deputy Chief Executive Officer and Chief Financial Officer, from October 2018. Prior to joining , Mr. Efron served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual listed plasma derived protein therapeutics company, from September 2011 to November 2017. Prior to that, Mr. Efron served as the CFO of NASDAQ listed RRsat Global Communications Ltd. (Nasdaq: RRST), from September 2005 to March 2011. Prior to that, Mr. Efron served in vario finance executive positions. Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Biness Administration from the Hebrew University of Jeralem and was granted a certified public accountant's license (non active) in Israel.
- Shai Lankry
Shai Lankry，2013年12月起，担任本公司的首席财务官、以色列地区经理。2006-2013，他任职于Johnson & Johnson旗下Ethicon Biosurgery的分部Omrix Biopharmaceuticals, Inc，最后的职务是生物集群财务总监，管理着全球各地的生物业务财务机构。此前，2004-2006，他是Kesselman & Kesselman审计业务的高级助理，专门从事高科技行业相关业务，这是PriceWaterhouseCoopers International Limited的成员公司。他是一名注册会计师，在以色列的Tel-Aviv University获得财务方向的工商管理硕士学位。
Shai Lankry has served as our Chief Financial Officer since April 2018. Mr. Lankry has more than 15 years of senior management experience in finance. Prior to joining Gamida Cell, from 2016 to 2018 Mr. Lankry served as a Finance Director at West Pharmaceutical Services Inc., leading the R&D and operations financials for the Israeli subsidiary. From 2013 to 2017 Mr. Lankry was the Chief Financial Officer and Israeli Site Manager of Macrocure Ltd. where he played an integral role in the company’s 2014 U.S. initial public offering and 2017 acquisition by Leap Therapeutics Inc. From 2006 to 2013 Mr. Lankry held senior finance positions at Ethicon Biosurgery, a Johnson & Johnson company, where in his most recent position, he was the Biologics Cluster Finance Director, managing the Biologics finance organization at multiple sites worldwide. Mr. Lankry is a licensed Israeli CPA and holds an M.B.A. in Finance from Tel-Aviv University.- Shai Lankry，2013年12月起，担任本公司的首席财务官、以色列地区经理。2006-2013，他任职于Johnson & Johnson旗下Ethicon Biosurgery的分部Omrix Biopharmaceuticals, Inc，最后的职务是生物集群财务总监，管理着全球各地的生物业务财务机构。此前，2004-2006，他是Kesselman & Kesselman审计业务的高级助理，专门从事高科技行业相关业务，这是PriceWaterhouseCoopers International Limited的成员公司。他是一名注册会计师，在以色列的Tel-Aviv University获得财务方向的工商管理硕士学位。
- Shai Lankry has served as our Chief Financial Officer since April 2018. Mr. Lankry has more than 15 years of senior management experience in finance. Prior to joining Gamida Cell, from 2016 to 2018 Mr. Lankry served as a Finance Director at West Pharmaceutical Services Inc., leading the R&D and operations financials for the Israeli subsidiary. From 2013 to 2017 Mr. Lankry was the Chief Financial Officer and Israeli Site Manager of Macrocure Ltd. where he played an integral role in the company’s 2014 U.S. initial public offering and 2017 acquisition by Leap Therapeutics Inc. From 2006 to 2013 Mr. Lankry held senior finance positions at Ethicon Biosurgery, a Johnson & Johnson company, where in his most recent position, he was the Biologics Cluster Finance Director, managing the Biologics finance organization at multiple sites worldwide. Mr. Lankry is a licensed Israeli CPA and holds an M.B.A. in Finance from Tel-Aviv University.